Industry

GENT, Belgium & TOKYO–(BUSINESS WIRE)–#IVD–H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows … [Read more…]

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, today reported select preliminary financial results for the year ended December 31, 2025 and other business updates. Select Financial Updates1 Generated $28.6 million of total revenue for the full year of 2025, including $23.4 million, … [Read more…]

SALT LAKE CITY–(BUSINESS WIRE)–PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced today that it will present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on Tuesday, March 17, 2026. Jason Murray, Chief Executive Officer … [Read more…]

Supporting advancement of complex intranasal therapies through clinical development CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its proprietary nasal delivery system is being utilized in LTR Pharma Limited’s (ASX:LTP) Phase II clinical study of SPONTAN®, an investigational intranasal spray … [Read more…]

Ticket sales now open; proceeds support St. Jude research and treatment ATLANTA–(BUSINESS WIRE)–Community leaders, philanthropists, and advocates across Georgia will gather for the 12th annual St. Jude Evening of Hope Gala, presented by longtime supporter HD Supply, on Saturday, April 18, 2026, at the InterContinental Buckhead Hotel. The event brings together supporters to celebrate and … [Read more…]

PITTSBURGH–(BUSINESS WIRE)–Mark Farrah Associates (MFA), https://www.markfarrah.com/, recently released a brief presenting a comparative analysis of the top Medicare Advantage (MA) plans for Maricopa County in Arizona (AZ) using new comparison tools found only in MFA’s Medicare Benefits Analyzer™ (MBA) product, a subscription-based dataset providing customers easy access to monthly enrollment information, as well as competitive … [Read more…]

Proven leader with over 15 years of experience successfully implementing financial and operational strategies across biotech industry WALTHAM, Mass.–(BUSINESS WIRE)–Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. … [Read more…]

BRUSSELS–(BUSINESS WIRE)–#EUStopBlockingHealthEquity–AIDS Healthcare Foundation (AHF) Europe will hold an advocacy action in Brussels on March 18 at 11:00 a.m. CET on Archimedes Street, followed by an in-person and virtual press conference at Press Club Brussels Europe titled “EU: Stop Blocking Health Equity,” urging European Commission (EC) decision-makers to support a legally binding Pathogen Access and … [Read more…]

Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO’s proprietary microsphere technology Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform INCHEON, Korea–(BUSINESS WIRE)–#Biosimilar–Samsung Bioepis Co., Ltd. … [Read more…]

SHANGHAI–(BUSINESS WIRE)–YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for YOLT-202, the company’s investigational in vivo base-editing therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The FDA approval enables the initiation of … [Read more…]